生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Sapanisertib (INK-128) demonstrates enzymatic inhibitory activity against mTOR with over 100-fold selectivity compared to PI3K kinases[1]. Sapanisertib (INK-128) selectively reduces the protein levels of YB1, MTA1, vimentin, and CD44 without affecting their mRNA levels in PC3 cells. It also diminishes the invasive capabilities of PC3 prostate cancer cells. Additionally, Sapanisertib (INK-128) impedes cancer cell migration beginning at 6 hours post-treatment, coinciding with the evident reduction in pro-invasion gene expression, and before any alterations in the cell cycle or overall global protein synthesis are observed[2]. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
MIA PaCa-2 | 1-100 nM | Cell Viability Assay | 72 h | inhibits cell viability dose dependently | 24971544 |
PANC-1 | 1-100 nM | Cell Viability Assay | 72 h | inhibits cell viability dose dependently | 24971544 |
PANC-1 | 50 nM | Cell Viability Assay | 24-96 h | inhibits cell viability time dependently | 24971544 |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.23mL 0.65mL 0.32mL |
16.16mL 3.23mL 1.62mL |
32.33mL 6.47mL 3.23mL |
参考文献 |
---|